Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsThe feasibility and safety of high-intensity focused ultrasound combined with low-dose external beam radiotherapy as supplemental therapy for advanced prostate cancer following hormonal therapy.A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceDuration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancerNrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.Intermittent versus continuous androgen suppression therapy: do we have consensus yet?Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.Cardiovascular risk during hormonal treatment in patients with prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Hormone therapy in the management of prostate cancer: evidence-based approachesNadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTSurveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialGermline predictors of androgen deprivation therapy response in advanced prostate cancerRadiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective StudyAdverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy.Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.Androgen suppression strategies for prostate cancer: is there an ideal approach?Pharmacotherapeutic management of locally advanced prostate cancer: current status.Testosterone in prostate cancer: the Bethesda consensus.Mathematically modelling and controlling prostate cancer under intermittent hormone therapySafety and tolerability of intermittent androgen deprivation therapy: a literature review.Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Landmarks in hormonal therapy for prostate cancer.Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?Management of cancer treatment-induced bone loss.Tumour heterogeneity and immune-modulationIntermittent versus continuous androgen deprivation therapy in advanced prostate cancer.Intermittent androgen deprivation therapy in advanced prostate cancer.Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
P2860
Q26747782-B5BB8BFD-E483-4AF4-847E-91213B57B6A5Q27022847-E57B961C-9E81-4A9B-A23E-BECA75B4893BQ28076622-90D9118C-57A0-4D5F-B89F-F611AEB3025BQ30449403-FD2D7AC8-C57C-4A18-B383-04D46091AF4AQ30780322-D021B5A3-35E6-4F48-B429-C28883C673C9Q33789117-08E0893B-6E08-43D0-AFE4-CED1A75840B7Q33899266-2BB93CFF-DA94-4B07-B1CC-4C8E6B6E93ACQ34001080-83BF8103-0164-4649-A539-608E04591F58Q34005286-77FFD1F9-D0FB-4F93-ADF9-61703903BF5DQ34111614-766A3968-BC55-4520-9DD7-CE07368FEBD8Q34437308-20A08276-A74C-4564-BC64-9A6F129D4A8CQ34502268-16854F94-B0F0-43B9-9D0A-24DF36546956Q34721165-6B92C751-976F-4B01-A5DD-6E51532520C7Q34997355-90BF8B9D-45B9-4C1B-9AFC-38D5E5CB24EEQ35034020-05B32D24-C0D2-415D-A049-054E4128818AQ35076432-A4F8DA26-4F5D-4F68-80B5-027D1CD7B409Q35215038-BE58569F-9C3D-48A8-A6B0-9AEEA655AC47Q35253783-353D5FB5-C54B-4F41-8B12-9BC21E62252AQ36512896-D82C3CAE-5F17-40FB-8685-ED0135F9E28CQ36581142-074E9D5D-5D3D-4107-BEE7-45903F61E632Q36854835-DE56DBB2-39CB-45D9-AF8B-EEBEC218C724Q37137452-BD095AC0-148A-426C-9209-42E2CFE0CCC0Q37283578-936410C3-F1E8-493D-9512-50A11147132BQ37554029-EF5A175D-8903-48C1-B384-C84E4BDE00D4Q37592301-D54150D1-7376-4DF3-BEBC-22AD067F5828Q37800061-06882EBB-7B7C-491C-A031-7C75AE6EADF2Q37850714-48DE3F6F-50EE-4EE0-BD33-D470DEBB7BA5Q37888666-0D3C0F23-A60B-42E3-AA71-51F7E9CDA5B2Q37963010-262E6EB0-9C1C-49D2-AB9A-006FEFDCBFEFQ37974505-04297FF6-3CBB-4D4A-8F92-B237D7672917Q37995670-C3F3C664-7D74-4DC0-BB1D-63E31CDDB0A1Q38016531-EF366C80-204A-4A80-831E-3BE0811DBC6FQ38023124-81811215-CE18-4EEB-8A5F-F2979D457805Q38050466-8C5C2B1A-4C0D-4C93-A340-00C29F274E13Q38077183-8F16DB8E-9CD4-4F36-96A0-AC99EDF57A8DQ38090917-3682D73A-B25F-4769-9D6C-5ED72B8742ACQ38105714-0D3DAD35-0079-419A-BAE2-B22B9DBBD298Q38108745-1574F6F9-7D34-4AA6-9291-81F0BAA70F2BQ38176254-8F23DBE6-E573-4DA4-B68A-974ADAEC01AFQ38179060-3BD517D2-B191-465D-B0F6-50B59A957271
P2860
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential benefits of intermit ...... atic review of the literature.
@en
Potential benefits of intermit ...... atic review of the literature.
@nl
type
label
Potential benefits of intermit ...... atic review of the literature.
@en
Potential benefits of intermit ...... atic review of the literature.
@nl
prefLabel
Potential benefits of intermit ...... atic review of the literature.
@en
Potential benefits of intermit ...... atic review of the literature.
@nl
P1433
P1476
Potential benefits of intermit ...... atic review of the literature.
@en
P2093
Per-Anders Abrahamsson
P356
10.1016/J.EURURO.2009.07.049
P407
P577
2009-08-07T00:00:00Z